Clinical Trials Browser

Interventional × Has results × VTX-2337 × Clear all

NCT02431559 2022-10-10

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Phase 1/2 Completed

53 enrolled 22 charts

Ovarian Neoplasms

NCT01836029 2019-10-29

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

195 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT01666444 2019-09-26

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Phase 2 Completed

297 enrolled 15 charts

Carcinoma, Ovarian Epithelial, Brenner Tumor, Fallopian Tube Neoplasms

NCT01289210 2019-09-25

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

Phase 1/2 Terminated

2 enrolled 4 charts

Lymphoma